ONCONasdaqPharmaceutical PreparationsFiscal year ends December 31

Onconetix, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.43−0.05 (-10.13%)

Close on Oct 19, 2026

Market cap: $965.06K
P/E (TTM): –
Dividend yield: –

Onconetix, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	0.82	2.52	0.06	–	–
Cost of Revenue	0.18	1.47	1.19	–	–
Gross Profit	0.63	1.06	-1.13	–	–
Research & Development	–	0.15	1.95	4.13	1.33
Selling, General & Admin	7.04	11	15	9.35	–
General & Administrative	–	–	–	9.35	2.09
Operating Expenses	18	58	35	13	3.42
Total Costs & Expenses	0.04	0.04	–	–	–
Operating Income	-18	-56	-36	-13	-3.42
Interest Expense	0.75	0.87	0.67	–	–
Interest & Investment Income	0.00	0.00	–	–	–
Other Non-Operating Income	3.83	-3.25	-1.39	0.06	–
Asset Impairment Charges	12	3.50	15	–	–
Gain (Loss) on Sale of Assets	-0.02	–	–	–	0.00
Legal Settlements	–	0.01	–	–	–
Pretax Income	-14	-60	-37	-13	–
Income Tax Expense	0.00	-1.05	-0.01	3,158,873	675,730
Net Income incl. Noncontrolling Interests	–	–	-37	-13	–
Net Income	-14	-59	-37	-13	-3.42
Preferred Dividends	–	–	–	0.10	–
Net Income to Common	-16	-59	-37	-14	-4.04
EPS (Basic)(per share)	-16.56	-1,823.39	-7,433.25	-3,740.00	-4,284.00
EPS (Diluted)(per share)	-16.56	-1,823.39	-7,433.25	-3,740.00	-4,284.00
Shares Outstanding (Basic, Weighted)(shares)	0.94	0.03	0.01	0.00	0.00
Shares Outstanding (Diluted, Weighted)(shares)	0.94	0.03	0.01	0.00	0.00
Dividend per Share(per share)	–	–	–	4,182.00	–
EBITDA	-18	-56	-36	-13	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 80.4%
Operating margin: -2525.0%
Net margin: -1578.8%
Return on equity, FY2025: -115.5%

Financial strength

Current ratio: 2.21
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 201.9%

Valuation

P/E ratio: –
Price to sales: 1.49
Price to book: 0.07
Dividend yield: –